Possible future steps could be the quantification of CXCR4 and markers of cell invasiveness, autophagy, and mTOR signalling, in biopsies from metastatic and non-metastatic melanoma patients, by immunohistochemistry. This evidence concerns the gene MTOR and melanoma.